Chien Te K. Tseng

TL;DR: The findings of a World Health Organization expert working group that is developing animal models to test vaccines and therapeutic agents for the treatment of COVID-19, and their relevance for preclinical testing, are reviewed.

TL;DR: These SARS-CoV vaccines all induced antibody and protection against infection with SARS -CoV, however, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARsCoV components was induced.

TL;DR: It is shown that CD81 cross-linking via immobilized E2 or mAbs specific for CD81 inhibits not only non major histocompatibility complex–restricted cytotoxicity mediated byNK cells but also interferon (IFN)-γ production by NK cells after exposure to interleukin (IL)-2, IL-12,IL-15, or CD16 cross- linking.

TL;DR: It is demonstrated that SARS-CoV nsp1 suppressed host innate immune functions, including type I IFN expression, in infected cells and suggested that Sars- CoV nSp1 most probably plays a critical role in SARS -CoV virulence.

TL;DR: Crystal structures indicated that EK1 can form a stable six-helix bundle structure with both short α-HCoV and long β-H CoV HR1s, further supporting the role of HR1 region as a viable pan-CoV target site.